Arthramid Vet

In this episode, equine veterinarian Dr Jack Egan discusses his practical approach to diagnosing and managing joint disease across racing, performance, and pleasure horses. He shares how his clinical decision-making has evolved, the importance of accurate diagnosis, and how treatment modalities fit into long-term management strategies. Dr Egan also explains where Arthramid has shifted his approach, including case selection, dosing considerations, and repeat treatment intervals. Through real-world cases, he highlights how thoughtful joint management can improve comfort, performance, and client relationships in everyday equine practice.

This episode is a replay of a recent live webinar. For the full video version including slides, diagrams, and live Q&A, please visit the Arthramid Canine YouTube channel (https://www.youtube.com/watch?v=BOwYo_ByFAA&t=17s)In this session, the panel examines the safety profile and practical use of 2.5% Arthramid (iPAAG) in both dogs and horses. Drawing on published research, global post‑market data, and extensive clinical experience, the discussion provides an evidence‑based overview of what veterinarians can expect when using iPAAG across different joints, patient types, and clinical scenarios.Key discussion themesCanine clinical safety and outcomesReal‑world clinical experience from more than 2,000 canine joint injectionsRetrospective owner‑reported outcomes showing transient soreness rates of 10–15%Prospective study findings: majority of dogs progressing comfortably to 12 monthsInjection technique considerations, especially for elbows and hipsUse in small or tight joints, including distal phalangeal jointsInfluence of age, chronicity and body condition on expected responseWhen and how concurrent therapies (PRP, corticosteroids) may be usedEquine research and synovial responseOverview of global equine safety data and long-term useHistology findings showing a transient, low‑grade macrophage responseClarification around misconceptions regarding synovial “foreign body” reactionsKey differences between early non‑septic flares and later‑onset septic presentationsNeedle placement and imaging guidance to reduce extra‑articular depositionAdverse events and management strategiesReview of global post‑marketing data (>90,000 syringes), showing very low AE ratesDifferentiating septic vs non‑septic flares, and appropriate first‑line responsesWhy synovial sampling, NSAIDs, and systemic antibiotics are typically sufficientAvoiding unnecessary synovectomies or intra-articular aminoglycosides in non‑septic presentationsTechnique and practical considerationsBest practices for aseptic prep, needle control, and sedation/anaesthesiaDose considerations based on pathology severityTiming of rehabilitation and why adjunct modalities (laser, shockwave) should wait 4–6 weeksImportance of monitoring, follow‑up assessment, and client communicationWe'd like to thank you panelists for this discussion: Dr. Courtney Campbell | Stitches Veterinary Surgery, Long Beach, CADr. Jess Gleesher | Skilo Sports Medicine, Woodstock, MDDr. Carl Maritado | MedVet Medical and Cancer Centers, Cincinnati, OHModerated by Dr. Meg Green | Technical Services Veterinarian, Contura Vet

This episode is a recording of a seminar held in Cambridge, New Zealand, featuring presentations from Professor Wayne McIlwraith and Dr. Leigh de Clifford, introduced by host Dr. Jason Lowe. If you wish to watch the full episode with slides, please refer to our YouTube channel.Professor Wayne McIlwraith, BVSc, PhD, DSc, FRCVS, DACVS, is a University Distinguished Professor at Colorado State University, founding director of the Orthopaedic Research Center, and namesake of the C. Wayne McIlwraith Translational Medicine Institute. A New Zealand native, he is a past president of both the American College of Veterinary Surgeons and the American Association of Equine Practitioners, an inductee into the International Equine Research Hall of Fame, and a recipient of the New Zealand Order of Merit for services to the veterinary industry. He has authored over 500 scientific publications and seven textbooks, and is recognized globally as a pioneer in equine arthroscopic surgery and joint disease research.Dr. Leigh de Clifford is the Technical Service Veterinarian for Contura Vet, with over 12 years of clinical and research experience using Arthramid across racing and equestrian disciplines worldwide.Dr. Jason Lowe, Chief Veterinary Officer for Contura Vet, opens the seminar with an overview of the Arthramid research timeline and the company's commitment to ongoing science across species.In this episode, you will learn:How 2.5% iPAAG integrates into the sub-intimal layer of the synovial membrane and why this mechanical pathway sets it apart from conventional drug-based therapiesThe significance of the FDA's classification of Arthramid as a veterinary medical device and what that distinction meansWhy synovitis is a major driver of osteoarthritis and how inflammation of the synovial membrane, not cartilage degradation alone, sits at the center of joint diseaseResults from the CSU carpal chip fragment model showing that Arthramid restored normal joint capsule elasticity in osteoarthritic joints, while untreated joints exhibited significantly increased stiffnessHow the macrophage-driven response to iPAAG is transient, peaking around 42 days and resolving by 90 days without fibrosis or granuloma formationEvidence of cartilage preservation in treated joints, including retained proteoglycan staining compared to controlsFindings from a retrospective analysis of 701 thoroughbred racehorses treated at a single practice in Melbourne over a seven-year period, including long-term safety data and career performance outcomes in 214 horsesWhy multiple injections in a single joint showed no increase in adverse events and no detrimental impact on race starts or career lengthThe limitations of corticosteroids in racing, including increased fracture hazard ratios after repeated use and tightening regulatory environmentsWhether you are a veterinarian looking for the latest research on iPAAG or a horse owner wanting to understand the science behind this treatment, this episode offers a comprehensive look at the evidence supporting Arthramid in equine joint health.Subscribe and share with your colleagues so you never miss an episode.Learn more at arthramid.com

This episode is a recording of a seminar Dr. Lisa Fortier presented in Cambridge, New Zealand. If you wish to watch the full episode with slides, please refer to our YouTube channel.Dr. Lisa Fortier, DVM, PhD, DACVS is the James Law Professor of Surgery at Cornell University, an inductee into the University of Kentucky Equine Research Hall of Fame, and the author of over 200 scientific papers on regenerative medicine, arthritis, and tendonitis. She also delivered the prestigious Frank J. Milne State-of-the-Art Lecture at the AAEP's 70th Annual Convention in 2024.In this wide-ranging conversation, Dr. Fortier breaks down what is actually happening inside the joint when we treat osteoarthritis, why the synovial membrane is the true target of intra-articular therapy, and how immunomodulation, not simply suppressing inflammation, is the key to improving long-term joint health.In this episode, you will learn:Why what you are treating when you inject a joint is not the cartilage but the synovial membrane and surrounding soft tissuesWhy osteoarthritis is now understood as an immune-mediated disease, not simply a wear and tear conditionHow macrophage polarization and T cell phenotype switching play a central role in joint disease progressionWhy early intervention matters, and the research pointing to IL-6 as a potential biomarker for predicting osteoarthritis after joint injuryThe limitations of corticosteroids, including steroid euphoria masking true lameness and increasing regulatory pressure in racingHow biologics such as PRP, IRAP, and polyacrylamide hydrogels offer immunomodulatory approaches that support functional tissue regenerationWhy more is not always better with platelet-rich plasma, and the importance of neutrophil-reduced formulationsDr. Fortier's practical protocol for repeat injections and when she chooses not to give a second doseWhether you are a veterinarian refining your approach to joint therapy or a horse owner looking to better understand the options available, this episode offers a science-led perspective on the evolving landscape of intra-articular care.Subscribe and share with your colleagues so you never miss an episode.Learn more at arthramid.com

In this episode of the Arthramid® In Practice podcast, Dr. Leigh de Clifford, Technical Service Veterinarian for Contura Vet, shares over 12 years of clinical experience using Arthramid 2.5% iPAAG in the management of equine osteoarthritis.Dr. de Clifford walks through the practical, case-by-case decisions that veterinarians face when working with Arthramid, from patient selection criteria and diagnostic workup to injection technique, dosing considerations and post-administration management.In this episode, you will learn:How to identify the right candidates for Arthramid treatment, including what clinical signs and imaging findings to look forWhy early intervention in the disease process can lead to quicker, stronger and longer-lasting outcomesPractical injection tips, including the use of a 21-gauge needle as a placement confirmation tool and how ultrasonography can support accurate delivery, particularly in stifle jointsWhen it may be appropriate to use Arthramid alongside other therapies such as NSAIDs or corticosteroids, and when to use it exclusivelyWhat to expect post-administration, including recommended rest protocols and timelines for return to workHow to approach repeat dosing, with independent data supporting safe use of multiple injections over a horse's career spanning up to 12 to 13 yearsHow to recognize and manage the rare occurrence of a joint flare, and why aggressive arthroscopic flushing should be avoidedDr. de Clifford also addresses common mistakes practitioners encounter, the safety profile he has observed over more than a decade of clinical use, and how GMP-certified manufacturing and the product's parallel use in human medicine reinforce confidence in its reliability.Whether you are new to using Arthramid or looking to refine your approach, this episode is packed with practical insight you can take straight into clinic.Subscribe and share with your colleagues so you never miss an episode.Learn more at arthramid.com

This episode is an audio recording of a live webinar presented by Dr. Matt Brunke. Please note that he refers to visual slides during the session. The video recording will be available to view on YouTube shortly. Join Dr. Matt Brunke, DVM, DACVSMR, as he presents “It's Not the Cartilage, It's the Synovium”, a deep dive into the evolving understanding of canine osteoarthritis. In this informative session, Dr. Brunke explores the critical role the synovium plays in the pathophysiology of osteoarthritis, modern approaches to diagnosis, and a review of current evidence-based intra-articular (IA) therapies.With certifications in rehabilitation, pain management, and acupuncture, and as a diplomate of the American College of Veterinary Sports Medicine and Rehabilitation, Dr. Brunke brings a big-picture, practical perspective to managing orthopedic and neurological conditions in dogs.Whether you're a veterinarian, rehab specialist, or veterinary nurse, this episode offers valuable insights into more targeted and effective strategies for OA treatment in canine patients.

This episode is a recording of a webinar run in partnership with VetPD and Contura Vet. Join panelists Dr Lea Walker  (DVM, DACVSMR) and Dr Cooper Williams  (VMD, DACVSMR, Certified ISELP Instructor) for a dynamic panel discussion on the use of diagnostic imaging in diagnosing joint disease. Our expert panel will explore how imaging findings influence treatment strategies and share cases where 2.5% iPAAG may serve as a beneficial treatment option. This interactive session promises valuable insights for veterinary professionals aiming to enhance their diagnostic and therapeutic approaches

This episode is a recording of a webinar run in partnership with VetPD and Contura Vet in April 2025. The webinar is also available to view on demand on the Arthramid Equine YouTube channel. Join experts Leigh de Clifford (BVSc, CertAVP, PGDipVPS, MRCVS), JD Conway (DVM), Megan Green (DVM), and Jason Lowe (MBA, BVSc., Cert EP) as they dive into the long-term use of 2.5% injectable polyacrylamide hydrogel (iPAAG) in equine performance horses. This insightful session covers:The physico-chemical properties of iPAAGThe latest research and clinical findingsPractical tips for case selection and post-treatment managementWhether you're currently using iPAAG or exploring its potential, this webinar delivers valuable, real-world insights for veterinary professionals.

Dr Jason Lowe sits down with Dr Becci Ireland of Central Lakes Equine to discuss her experience with ArthramidVet, how she got on to it, some of her most memorable cases in using it and how she speaks to her clients about ArthramidVet.

Tune into esteemed researcher and veterinarian, Dr Lisa Fortier who, alongside Dr Jason Lowe, discussed Intra-Articular Approaches to Osteoarthritis and management of the disease in equines and companion animals at a recent seminar. Lisa gave an informative, science-based talk, introducing some of the exciting new research and gave updates about treatment options available for osteoarthritis in animals as we continue to learn more about this disease. Lisa covers the pro's and con's of all popular biological treatments, including PRP, IRAP, Pro-Stride, Stem cells, A2M and Polyacrylamide Hydrogels (Noltrex & ArthramidVet). This podcast is the recording of a seminar, if you would like to view a video recording, including the presentation slides, visit:  https://arthramid.com.au/dr-lisa-fortier-seminar/

This episode is a recording of a webinar run by the Australian Veterinarian Association in which Dr Jason Lowe, Dr Stuart Vallance and Dr Marc Koene present the lastest research and findings on ArthramidVet. Listen in while they discuss the use of 2.5% injectable iPAAG in equine sports medicine and include recent updates on what we are learning about the role of macrophage activation in healthy and osteoarthritic joints. Please note, as this is a recording of a webinar, at times the presenters speak to slides. If you would like to view the video webinar, please head to https://www.ava.com.au/education-events/education-and-events-search/event-detail/?eid=EV001671&_cldee=4kO64JMQLrRIKMGf9Q0gC7DfzHYyDl_gHoc8_n7msf-ctHGTpnCmIApWXPFfatIn&recipientid=contact-d08c231c8812eb11a836000d3ad1b063-9d053f0c80654bf2b1819a9031037028&esid=308d9530-e8c6-ee11-a87e-000d3ad1b063

This audio is from a presentation that was part of the Australian Veterinary Association Vet Fest Marketplace 2021. Dr Florent David is head of Clinical Services at the Qatar Equine Veterinary Medical Center and a registered specialist with both the American and European Colleges of Veterinary Science. Dr David has years of experience using 2.5% iPAAG in clinical cases, and has also co-authored on published papers. In this 40 minute talk Dr David goes through the research behind the product, published studies, safety and efficacy, and takes questions from the audience

In this episode we talk to Dr Leigh de Clifford, clinical veterinarian and published author, about where he finds Arthramid Vet most useful in practice.

Dr Leigh de Clifford discusses the Published Literature to date for the development of the use of 2.5% PAAG in treating lameness

In Episode 5 we talk to Australian legend Dr Kim McKellar, Equine Veterinarian, about his experiences of Arthramid Vet from over 50 years in clinical practice; "I wish I had this product 30 years ago".

In Episode 4 of our series we meet with Dr Aziz Tnibar, another of the original researcher's behind the use of 2.5% PAAG in the treatment of lameness and osteoarthritis in animals. Dr Tnibar says Arthramid Vet is "the best treatment we have for OA" and discusses the importance of an accurate diagnosis and good injection technique to achieve results > 82%.

Top German Equine Veterinarian, Dr Marc Koene claims Arthramid Vet is "A major game changer in orthopaedic treatment". Dr Koene shares his insights having worked with the product for over 8 years as one of the original researchers.

This second episode in our series discusses how to use Arthramid Vet in the management of joint lameness and osteoarthritis in horses.

The first in a series of podcasts from Innovative Medical Solutions to introduce Arthramid Vet. An exciting new dynamic tissue scaffold hydrogel for the long lasting and effective treatment of pain and joint lameness in animals.